The conventional live or killed vaccines, though quite successful, have a few shortcomings which make a chance to develope new kinds of vaccines1). For some reasons, new approaches are being considered for vaccine development, which are not based on the entire organism. These include recombinant vaccines, DNA vaccines, peptide vaccines and therapeutic vaccines. I will mainly focused on recombinant vaccines are created by utilizing bacteria or yeast to produce large quantities of a single viral protein. Up to now, recombinant vaccines licensed in our country are hepatitis B vaccine and HPV vaccine. The success of the first VLP vaccine in humans, the yeast-grown HBV vaccine, was encouraging for the development of additional VLP vaccines. The subsequent successful immunization programs for HPV suggest that VLP made by expression of recombinant capsid proteins may be a platform technology for all non-enveloped viruses that emerge as candidates for vaccine protection2). I will also mention a recent direction, namely, the development of recombinant virus vaccines as well as in manufacturing and quality control for recombinant vaccines according to related guideline published by KFDA.
저자
Dokeun Kim [ Viral Vaccines Team, Biologics Headquarters, Korea Food & Drug Administration ]
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동